Aardvark Therapeutics, Inc. (AARD)
1.35
+0.18
(+15.38%)
USD |
NASDAQ |
Nov 09, 11:58
Aardvark Therapeutics Enterprise Value : -47.59M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -47.59M |
| November 05, 2026 | -48.90M |
| November 04, 2026 | -45.62M |
| November 03, 2026 | -46.28M |
| November 02, 2026 | -46.93M |
| October 30, 2026 | -43.43M |
| October 29, 2026 | -41.68M |
| October 28, 2026 | -40.15M |
| October 27, 2026 | -44.74M |
| October 26, 2026 | -49.56M |
| October 23, 2026 | -42.77M |
| October 22, 2026 | 13.25M |
| October 21, 2026 | 23.32M |
| October 20, 2026 | 12.16M |
| October 19, 2026 | 8.654M |
| October 16, 2026 | 9.529M |
| October 15, 2026 | 11.28M |
| October 14, 2026 | 11.72M |
| October 13, 2026 | 15.22M |
| October 12, 2026 | 24.19M |
| October 09, 2026 | 30.98M |
| October 08, 2026 | 29.88M |
| October 07, 2026 | 35.35M |
| October 06, 2026 | 37.10M |
| October 05, 2026 | 41.04M |
| Date | Value |
|---|---|
| October 02, 2026 | 36.01M |
| October 01, 2026 | 42.14M |
| September 30, 2026 | 42.14M |
| September 29, 2026 | 43.89M |
| September 28, 2026 | 42.14M |
| September 25, 2026 | 37.54M |
| September 24, 2026 | 48.26M |
| September 23, 2026 | 48.48M |
| September 22, 2026 | 52.64M |
| September 21, 2026 | 48.70M |
| September 18, 2026 | 44.54M |
| September 17, 2026 | 47.83M |
| September 16, 2026 | 39.51M |
| September 15, 2026 | 36.67M |
| September 14, 2026 | 48.26M |
| September 11, 2026 | 39.07M |
| September 10, 2026 | 36.45M |
| September 09, 2026 | 34.48M |
| September 08, 2026 | 43.45M |
| September 04, 2026 | 44.54M |
| September 03, 2026 | 52.20M |
| September 02, 2026 | 57.02M |
| September 01, 2026 | 56.36M |
| August 31, 2026 | 60.30M |
| August 28, 2026 | 53.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 692.32B |
| Bristol Myers Squibb Co. | 159.24B |
| ANI Pharmaceuticals, Inc. | 1.715B |
| Corcept Therapeutics, Inc. | 7.597B |
| Veru, Inc. | 13.04M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.39M |
| Total Expenses (Quarterly) | 14.39M |
| EPS Diluted (Quarterly) | -0.6586 |
| Earnings Yield | -237.4% |
| Normalized Earnings Yield | -237.43 |